ARA- 290 – 16MG

ARA-290 Clinical Summary

ARA-290: Mechanism, Indications, and Evidence

Mechanism of Action

ARA-290 (also known as Cibinetide, pHBSP) is a synthetic nonerythropoietic peptide derived from erythropoietin’s helix B surface. It selectively activates the innate repair receptor (IRR, CD131/EPOR heterodimer), mediating tissue protection and anti-inflammatory effects without stimulating erythropoiesis.^[1][2][3][4] ARA-290 inhibits NF-κB phosphorylation, reduces reactive oxygen species (ROS) production, and suppresses NLRP3 inflammasome activation in Schwann cells after peripheral nerve injury.^[5] It also modulates immune cell populations, increasing regulatory T cells and Th2 polarization while suppressing Th1/Th17 responses.^[3][4]

Clinical Indications and Evidence

Neuropathic Pain:

• Long-term relief of tactile and cold allodynia in rodent models of peripheral nerve injury, dependent on β-common receptor activation.^[2][6]
• In humans with type 2 diabetes and painful neuropathy, daily subcutaneous ARA-290 (4 mg for 28 days) improved neuropathic symptoms (PainDetect), increased corneal nerve fiber density, and showed a favorable safety profile.^[1]
• Dose-dependent suppression of spinal microglia reactivity correlates with sustained analgesic effects.^[6]
• Direct antagonism of TRPV1 channels may contribute to analgesic properties.^[7]

Metabolic Control in Diabetes:

• Phase 2 data: improved HbA1c and lipid profiles alongside neuropathic symptom improvement and corneal nerve fiber density in type 2 diabetes.^[1]

Neuroinflammatory and Autoimmune Disorders:

• In experimental autoimmune neuritis and encephalomyelitis, ARA-290 reduced disease severity, promoted nerve regeneration/remyelination, and suppressed inflammatory cytokines (IL-1β, IL-17, TNF-α, IFN-γ, iNOS, MMP9, T-bet).^[3][4]
• Modulates T cell differentiation and macrophage activation, favoring anti-inflammatory phenotypes.^[3][4]

Alzheimer’s Disease (Preclinical):

• Early systemic administration in APP/PS1 mice decelerated amyloid-β pathology and improved cognition, associated with increased Ly6C patrolling monocytes and enhanced Aβ clearance.^[8]

Safety

ARA-290 is reported to be devoid of erythropoietic and cardiovascular side effects associated with erythropoietin.^{[1][2][3][4][9][6]} Clinical trials at studied doses have not identified significant safety issues.^[1]

Summary

ARA-290 is a promising nonerythropoietic peptide with preclinical and early clinical evidence for neuropathic pain, metabolic control in diabetes, and neuroinflammatory conditions. Its actions include anti-inflammatory, neuroprotective, and immunomodulatory effects. While 4 mg daily has human data support, higher doses such as 16 mg lack published safety/efficacy data.^[1]

References

1. Brines M, Dunne AN, van Velzen M, et al. Molecular Medicine. 2015;20:658-66. doi:10.2119/molmed.2014.00215.
2. Swartjes M, Morariu A, Niesters M, et al. Anesthesiology. 2011;115(5):1084-92. doi:10.1097/ALN.0b013e31822fcefd.
3. Liu Y, Luo B, Han F, et al. PLoS One. 2014;9(3):e90942. doi:10.1371/journal.pone.0090942.
4. Chen H, Luo B, Yang X, et al. J Neuroimmunol. 2014;268(1-2):64-70. doi:10.1016/j.jneuroim.2014.01.006.
5. Liu G, Li W, Jiang S, et al. Eur J Pharmacol. 2025;997:177610. doi:10.1016/j.ejphar.2025.177610.
6. Swartjes M, van Velzen M, Niesters M, et al. Molecular Pain. 2014;10:13. doi:10.1186/1744-8069-10-13.
7. Zhang W, Yu G, Zhang M. Peptides. 2016;76:73-9. doi:10.1016/j.peptides.2016.01.003.
8. Al-Onaizi MA, Thériault P, Lecordier S, et al. Brain Behav Immun. 2022;99:363-382. doi:10.1016/j.bbi.2021.07.016.
9. Pulman KG, Smith M, Mengozzi M, Ghezzi P, Dilley A. Neuroscience. 2013;233:174-83. doi:10.1016/j.neuroscience.2012.12.022.